Upfront surgery or definitive radiotherapy for p16+ oropharyngeal cancer. A GETTEC multicentric study.
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Culié Dorian, Schiappa Renaud, Modesto Anouchka, Viotti Julien, Chamorey Emmanuel, Dassonville Olivier, Poissonnet Gilles, Bizeau Alain, Vergez Sebastien, Dupret-Bories Agnes, Fakhry Nicolas, Santini Laure, Lallemant Benjamin, Chambon Guillaume, Sudaka Anne, Peyrade Frederic, Saada-Bouzid Esma, Benezery Karen, Jourdan-Soulier Florence, Chapel Françoise, Ramay Anne Sophie, Roger Pascal, Galissier Thibault, Coste Valérie, Ben Lakdar Aicha, Guerlain Joanne, Mirghani Haitham, Gorphe Phillipe, Guelfucci Bruno, Garrel Renaud, Temam Stephane, Bozec Alexandre
Аннотация
METHODS: All p16-positive OPSCCs treated from 2009 to 2014 in 7 centers were retrospectively included and classified according to the therapeutic strategy: surgical strategy (surgery ± adjuvant radiotherapy and chemotherapy) vs. non-surgical strategy (definitive radiotherapy ± chemotherapy). Univariate, multivariate propensity score matching analyses were performed to compare overall (OS), disease-specific (DSS) and recurrence-free survival (RFS).
RESULTS: 382 patients were included (surgical group: 144; non-surgical group: 238). Five-year OS, DSS and RFS were 89.2, 96.8 and 83.9% in the surgical group and 84.2, 87.1 and 70.4% in the non-surgical group, respectively. These differences were statistically significant for DSS and RFS after multivariate analysis, but only for RFS after propensity score matching analysis.
CONCLUSION: In p16+ OPSCC patients, upfront surgery results in higher RFS than definitive radiotherapy ± chemotherapy but does not impact OS.